Vical, Aventis amend gene delivery deal

The companies restructured certain licensing deals for AVE's Aventis Pasteur subsidiary to use VICL's gene delivery technologies to treat infectious and neurodegenerative diseases. As restructured, Aventis Pasteur will return to VICL all rights related to these areas and instead license the technology for oncology. VICL said it will receive a license fee and that the restructuring does not change its 2001 burn rate. ...